Oxytocin: the first peptide hormone made in a lab, and the medicine it became
Long before GLP-1 drugs, a nine-amino-acid hormone became the first peptide hormone chemists ever built from scratch, and it's still used in hospital delivery rooms today. Oxytocin's story shows what a peptide looks like when the research works out: a Nobel Prize, an approved medicine and a cousin molecule that WHO recommends for preventing dangerous bleeding after birth.
Facts are as of November 2, 2026. Sources, with retrieval dates, are at the bottom.
Oxytocin at a glance
- Oxytocin is a nonapeptide, a chain of nine amino acids, and the Pitocin label notes it is found in pituitary extracts from mammals. [V]
- Vincent du Vigneaud won the 1955 Nobel Prize in Chemistry, cited in part for being first to build a polypeptide hormone from scratch. That hormone was oxytocin. [V]
- Pitocin, a synthetic oxytocin, is an FDA-approved prescription medicine for specific labor and post-birth uses in a hospital. It is not approved for elective induction of labor. [V]
- A 2018 trial in nearly 30,000 women found heat-stable carbetocin, a lab-made oxytocin analogue, noninferior to oxytocin on its main bleeding outcome. [V]
- The largest pediatric trial of oxytocin nasal spray in autism, published in 2021, found no difference from placebo on social measures. [V]
A small molecule with a big job
The posterior lobe of the pituitary gland holds two closely related hormones: oxytocin and vasopressin. The Nobel presentation speech for 1955 explains that oxytocin stimulates contractions of the uterus and milk release, while vasopressin raises blood pressure and acts on the kidneys. [V] The Pitocin label notes that the two molecules differ in only two of their amino acids, and that this likely explains why even pure oxytocin has some blood-pressure and water-holding effects at high exposure. [V]
That closeness was also a practical problem. Early hormone extracts from animal glands mixed the two together. The current Pitocin label explains that its oxytocin is made synthetically so that it won't carry stray vasopressin or other small polypeptides. [V] Our natural vs synthetic peptides page uses this as an example of a lab-made version being the cleaner one.
How du Vigneaud built it
The 1955 presentation speech walks through the work in steps. As early as 1933, du Vigneaud found a high share of sulfur in impure pituitary preparations, and it seemed to track with their activity. [V] His team then worked out the order of the building blocks: a ring closed by a bond between two sulfur atoms, with a short tail. [V] The last step was the hard one. They had to assemble the chain piece by piece, close the ring and then check whether the result behaved like the natural hormone. According to the speech, the lab-made chain matched the natural hormone. [V]
“for his work on biochemically important sulphur compounds, especially for the first synthesis of a polypeptide hormone”
Why did that matter beyond one hormone? Before this, a peptide hormone came from animal tissue or not at all. Showing that chemists could build one, and prove it was the same molecule, opened the door to designed variations on natural peptides. The GLP-1 drugs, for example, were built to mimic a natural gut hormone. Our peptide medicines timeline puts the 1955 prize next to insulin, Humulin and the GLP-1 era.
What the approved medicine is for
Pitocin's label is unusually specific about who it is for and where. It lists uses before birth, such as starting labor when there is a medical reason, for example preeclampsia near term or maternal diabetes, and uses after birth, such as helping the uterus contract and controlling bleeding. [V] It also carries an important notice: because the data are inadequate to judge benefits against risks, Pitocin is not indicated for elective induction, meaning starting labor with no medical reason. [V]
The label says that when Pitocin is used to start or strengthen labor, it should be given only with adequate medical supervision in a hospital, with trained staff watching continuously. [V] Its warnings include water intoxication, a serious complication the label attributes to the hormone's built-in antidiuretic (water-holding) effect. [V] The label also gives a short plasma half-life, roughly 1 to 6 minutes, which is part of why it's used under close watch. [V]
FDA's Drugs@FDA data lists the current Pitocin application, NDA 018261, with an original approval date of November 19, 1980. [V] Oxytocin was in medical use before that; this date belongs to the application now on file, not to the first use of the hormone. [U]
The heat-stable cousin
Oxytocin has a weakness that matters in much of the world: it needs refrigeration. WHO's 2018 guideline says oxytocin requires refrigerated transport and storage at 2 to 8 °C. [V] That is a real obstacle where the cold chain is unreliable, and WHO says postpartum hemorrhage is linked to nearly a quarter of maternal deaths worldwide. [V]
Carbetocin is a long-acting synthetic analogue of oxytocin, in WHO's description. [V] A heat-stable form was tested head to head against oxytocin in the CHAMPION trial, published in the New England Journal of Medicine in 2018. The trial randomized 29,645 women at 23 sites in 10 countries. [V] The main outcome, losing 500 ml of blood or more or needing an added medicine, occurred in 14.5% of the carbetocin group and 14.4% of the oxytocin group, which met the trial's test for noninferiority. [V] For the rarer outcome of severe bleeding (at least 1,000 ml), the rates were 1.51% and 1.45%, and noninferiority was not shown because there were too few events to be confident either way. [V]
- 29,645women randomized in the CHAMPION trial, 23 sites in 10 countries (RCT) [V]
- 14.5% vs 14.4%main bleeding outcome, carbetocin vs oxytocin (noninferior) [V]
- 1–6 minoxytocin's plasma half-life, per the Pitocin label [V]
WHO's 2018 update recommends carbetocin for preventing postpartum hemorrhage where it costs about the same as other effective options, and notes that its heat-stable form doesn't need cold-chain storage. [V] That's a good example of a modified peptide solving a practical problem the natural one couldn't. We found no carbetocin application in FDA's Drugs@FDA data when we checked, so it doesn't appear to be FDA-approved in the US. [V]
The "love hormone" research
Outside the delivery room, oxytocin has a popular nickname tied to bonding and trust, and it has drawn a lot of research interest in social behavior. The strongest test of one idea came in 2021. A phase 2 trial that ran 24 weeks and compared against placebo enrolled 290 children and teens with autism compared oxytocin nasal spray with placebo. [V] The main social-withdrawal score improved by 3.7 points with oxytocin and 3.5 with placebo, a difference that wasn't significant, and secondary measures generally didn't differ either. [V] Side effects were similar between groups. [V]
Claim
"Oxytocin spray improves social skills."
What research shows
- Human (randomized controlled trial)
In the largest pediatric autism trial, published in NEJM in 2021, oxytocin and placebo groups changed by about the same amount over 24 weeks. [V]
What is unknown
Whether other groups of people, other outcomes or other ways of giving it would show something different. One trial answers one question well; it doesn't close every related one.
This card describes the kind of research that exists.
That result doesn't make oxytocin less important as a medicine. It shows the difference between a well-understood hormone with an approved use and a newer idea that still has to earn its place in trials.
Peptide Policy Watch
Oxytocin: the first peptide hormone made in a lab, and the medicine it became
Printable checklist
Questions for your clinician
Questions this page raises, worth bringing to a clinician or pharmacist familiar with your health history.
- If oxytocin is part of my birth plan, what is the medical reason, and what are the alternatives?
- How will I be monitored while it's in use, and what side effects should the team watch for?
- Is an oxytocin product I've seen outside a pharmacy the same as the approved medicine?
- What does the research say about oxytocin for the specific question I'm asking about?
Print view Select it, then use your browser’s Print command to print only this box.
Limits and unknowns
We read the Pitocin label, FDA's Drugs@FDA data, the Nobel Prize pages, WHO's 2018 guideline and two NEJM abstracts. We did not read the full trial papers, so details beyond the abstracts aren't covered here. [V] WHO may have revised its guidance after 2018; we found the 2018 update to be the version linked from its publication page on November 2, 2026. [U] Drugs@FDA covers applications in its database; it isn't a full history of when oxytocin first entered US medicine. [U] This page describes research and labeling. It isn't advice about labor, birth or any treatment.
Why it matters for peptide news
Oxytocin is a reminder that peptides are not a fringe category. One of the earliest triumphs of modern chemistry was a peptide, and its descendants are standard medicines. The same path from discovery to lab synthesis to approved label is what any newer peptide would have to travel, and our evidence ladder shows where most newer ones sit on it today.
What to watch next
- Pitocin label updates on DailyMed. The version we read was published May 21, 2026. [V]
- Any FDA application for carbetocin, which would show up in Drugs@FDA. [U]
- New WHO guidance on preventing postpartum hemorrhage. [U]
Sources (retrieved November 2, 2026 unless noted)
- DailyMed, Pitocin (oxytocin) prescribing information, Par Health, label version published May 21, 2026 (retrieved November 1, 2026) [V] — https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e5a66fc-e507-497c-b5ce-44a8c95898ad
- NobelPrize.org, "The Nobel Prize in Chemistry 1955," summary [V] — https://www.nobelprize.org/prizes/chemistry/1955/summary/
- NobelPrize.org, Nobel Prize in Chemistry 1955, presentation speech [V] — https://www.nobelprize.org/prizes/chemistry/1955/ceremony-speech/
- NobelPrize.org, Vincent du Vigneaud, biographical [V] — https://www.nobelprize.org/prizes/chemistry/1955/vigneaud/biographical/
- openFDA Drugs@FDA API, Pitocin, NDA 018261 (original approval November 19, 1980) [V] — https://api.fda.gov/drug/drugsfda.json?search=openfda.brand_name:%22PITOCIN%22
- openFDA Drugs@FDA API, search for carbetocin (no matches) [V] — https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22carbetocin%22
- WHO, "WHO recommendations: uterotonics for the prevention of postpartum haemorrhage," 2018 update, December 20, 2018 [V] — https://www.who.int/publications/i/item/9789241550420
- Widmer M, et al., "Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth," New England Journal of Medicine, August 2018 (abstract via Europe PMC) [V] — https://pubmed.ncbi.nlm.nih.gov/29949473/
- Sikich L, et al., "Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder," New England Journal of Medicine, October 2021 (abstract via Europe PMC) [V] — https://pubmed.ncbi.nlm.nih.gov/34644471/
Spot a mistake? See how we source and our corrections policy.
Image: AI-generated. Image credits